SELB – Selecta Biosciences, SEL-212 Data

When:
September 1, 2018 @ 11:14 am – September 30, 2018 @ 12:14 pm
2018-09-01T11:14:00-04:00
2018-09-30T12:14:00-04:00

SELB – Selecta Biosciences, is due to present data from patients receiving five monthly doses of SEL-212, expected to be presented at Q3 medical conferenceSEL-212 (Most likely in September). https://stocksnewsfeed.com/selecta-biosciences-presents-data-from-ongoing-phase-2-trial-of-sel-212-in-development-for-chronic-severe-gout-at-eular-2018/

Since we still have a few months until the catalyst, I would like to swing this a few times according to bullish chart patterns, into the catalyst. Should slowly creep upwards into the $16 range.

According to Finviz, SELB currently has 3.82/Share and 17.37M Float, which should give it enough $ to operate for a year. SELB had some insider buying back in November 2017 from $9-Mid $10’s.

#SELB SEC Filings: https://selectabio.gcs-web.com/financial-information/sec-filings